Why Did Immutep Halt Its Pivotal NSCLC Trial After Early Data?

Trial Discontinuation Shakes Immutep’s NSCLC Ambitions

Immutep Limited, a biotechnology company specialising in immunotherapies, has announced the discontinuation of its TACTI-004 Phase III clinical trial evaluating eftilagimod alfa (efti) in first-line treatment of non-small cell lung cancer (NSCLC). The decision follows a planned interim futility analysis conducted by an Independent Data Monitoring Committee (IDMC), which concluded that the trial was unlikely to meet its primary efficacy endpoints.

The TACTI-004 study was a global, randomised, double-blind trial involving approximately 756 patients across more than 150 sites in over 25 countries. It tested the combination of efti, a novel MHC Class II agonist designed to activate the immune system, with Merck’s KEYTRUDA and chemotherapy, against a control arm without efti. The dual primary endpoints were progression-free survival and overall survival.

Unexpected Setback Amidst a Promising Pipeline

Immutep’s CEO, Marc Voigt, expressed disappointment and surprise at the futility outcome, noting efti’s positive performance in other clinical trials. The company is now conducting a thorough review of the data to understand the underlying reasons for the trial’s failure to demonstrate sufficient efficacy in this indication.

Despite this setback, Immutep remains committed to advancing its immunotherapy pipeline. The halt of TACTI-004 is expected to extend the company’s cash runway well beyond the previously guided Q2 2027 timeframe, providing additional runway to focus resources on other promising programs and indications where efti is being evaluated, such as head and neck cancer, soft tissue sarcoma, and breast cancer.

Strategic and Financial Implications

With enrolment stopped and the study entering an orderly wind down phase, Immutep will ensure appropriate patient follow-up and site closures in line with regulatory and ethical standards. The company plans to update the market on its revised cash position and capital allocation priorities once the full analysis of the TACTI-004 data is complete.

This development underscores the inherent risks in late-stage clinical trials, especially in oncology where complex immune mechanisms and tumour heterogeneity can impact outcomes. Investors will be watching closely for Immutep’s next moves, including potential pivots or partnerships to maximise the value of its LAG-3 focused immunotherapy platform.